Published October 10, 2024 | Version v1
Journal Open

Satiety hormone LEAP2 after low-calorie diet with/without Endobarrier insertion in obesity and type 2 diabetes mellitus (supplementary material)

  • 1. ROR icon Imperial College London

Description

Supplementary material for publication

Files

Emini Bhargava LEAP2 obesity T2DM LCD DJBL J Endo Soc 2024 Suppl material.pdf

Additional details

Funding

UK Research and Innovation
Human experimental medicine studies of gut hormone LEAP2, an endogenous ghrelin antagonist and target for obesity, diabetes, cachexia and addiction MR/T017279/1
UK Research and Innovation
A randomized controlled trial of a duodenal sleeve bypass device (Endobarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes MC_PC_14139